Cargando…
Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia
BACKGROUND: Epidemiological studies show wide variability in the occurrence of cannabis smoking and related disorders across countries. This study aims to estimate cross-national variation in cannabis users' experience of clinically significant cannabis-related problems in three countries of th...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2863162/ https://www.ncbi.nlm.nih.gov/pubmed/20331880 http://dx.doi.org/10.1186/1471-2458-10-152 |
_version_ | 1782180745239855104 |
---|---|
author | Fiestas, Fabian Radovanovic, Mirjana Martins, Silvia S Medina-Mora, Maria E Posada-Villa, Jose Anthony, James C |
author_facet | Fiestas, Fabian Radovanovic, Mirjana Martins, Silvia S Medina-Mora, Maria E Posada-Villa, Jose Anthony, James C |
author_sort | Fiestas, Fabian |
collection | PubMed |
description | BACKGROUND: Epidemiological studies show wide variability in the occurrence of cannabis smoking and related disorders across countries. This study aims to estimate cross-national variation in cannabis users' experience of clinically significant cannabis-related problems in three countries of the Americas, with a focus on cannabis users who may have tried alcohol or tobacco, but who have not used cocaine, heroin, LSD, or other internationally regulated drugs. METHODS: Data are from the World Mental Health Surveys Initiative and the National Latino and Asian American Study, with probability samples in Mexico (n = 4426), Colombia (n = 5,782) and the United States (USA; n = 8,228). The samples included 212 'cannabis only' users in Mexico, 260 in Colombia and 1,724 in the USA. Conditional GLM with GEE and 'exact' methods were used to estimate variation in the occurrence of clinically significant problems in cannabis only (CO) users across these surveyed populations. RESULTS: The experience of cannabis-related problems was quite infrequent among CO users in these countries, with weighted frequencies ranging from 1% to 5% across survey populations, and with no appreciable cross-national variation in general. CO users in Colombia proved to be an exception. As compared to CO users in the USA, the Colombia smokers were more likely to have experienced cannabis-associated 'social problems' (odds ratio, OR = 3.0; 95% CI = 1.4, 6.3; p = 0.004) and 'legal problems' (OR = 9.7; 95% CI = 2.7, 35.2; p = 0.001). CONCLUSIONS: This study's most remarkable finding may be the similarity in occurrence of cannabis-related problems in this cross-national comparison within the Americas. Wide cross-national variations in estimated population-level cumulative incidence of cannabis use disorders may be traced to large differences in cannabis smoking prevalence, rather than qualitative differences in cannabis experiences. More research is needed to identify conditions that might make cannabis-related social and legal problems more frequent in Colombia than in the USA. |
format | Text |
id | pubmed-2863162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28631622010-05-04 Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia Fiestas, Fabian Radovanovic, Mirjana Martins, Silvia S Medina-Mora, Maria E Posada-Villa, Jose Anthony, James C BMC Public Health Research article BACKGROUND: Epidemiological studies show wide variability in the occurrence of cannabis smoking and related disorders across countries. This study aims to estimate cross-national variation in cannabis users' experience of clinically significant cannabis-related problems in three countries of the Americas, with a focus on cannabis users who may have tried alcohol or tobacco, but who have not used cocaine, heroin, LSD, or other internationally regulated drugs. METHODS: Data are from the World Mental Health Surveys Initiative and the National Latino and Asian American Study, with probability samples in Mexico (n = 4426), Colombia (n = 5,782) and the United States (USA; n = 8,228). The samples included 212 'cannabis only' users in Mexico, 260 in Colombia and 1,724 in the USA. Conditional GLM with GEE and 'exact' methods were used to estimate variation in the occurrence of clinically significant problems in cannabis only (CO) users across these surveyed populations. RESULTS: The experience of cannabis-related problems was quite infrequent among CO users in these countries, with weighted frequencies ranging from 1% to 5% across survey populations, and with no appreciable cross-national variation in general. CO users in Colombia proved to be an exception. As compared to CO users in the USA, the Colombia smokers were more likely to have experienced cannabis-associated 'social problems' (odds ratio, OR = 3.0; 95% CI = 1.4, 6.3; p = 0.004) and 'legal problems' (OR = 9.7; 95% CI = 2.7, 35.2; p = 0.001). CONCLUSIONS: This study's most remarkable finding may be the similarity in occurrence of cannabis-related problems in this cross-national comparison within the Americas. Wide cross-national variations in estimated population-level cumulative incidence of cannabis use disorders may be traced to large differences in cannabis smoking prevalence, rather than qualitative differences in cannabis experiences. More research is needed to identify conditions that might make cannabis-related social and legal problems more frequent in Colombia than in the USA. BioMed Central 2010-03-23 /pmc/articles/PMC2863162/ /pubmed/20331880 http://dx.doi.org/10.1186/1471-2458-10-152 Text en Copyright ©2010 Fiestas et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research article Fiestas, Fabian Radovanovic, Mirjana Martins, Silvia S Medina-Mora, Maria E Posada-Villa, Jose Anthony, James C Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia |
title | Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia |
title_full | Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia |
title_fullStr | Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia |
title_full_unstemmed | Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia |
title_short | Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia |
title_sort | cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the united states, mexico, and colombia |
topic | Research article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2863162/ https://www.ncbi.nlm.nih.gov/pubmed/20331880 http://dx.doi.org/10.1186/1471-2458-10-152 |
work_keys_str_mv | AT fiestasfabian crossnationaldifferencesinclinicallysignificantcannabisproblemsepidemiologicevidencefromcannabisonlysmokersintheunitedstatesmexicoandcolombia AT radovanovicmirjana crossnationaldifferencesinclinicallysignificantcannabisproblemsepidemiologicevidencefromcannabisonlysmokersintheunitedstatesmexicoandcolombia AT martinssilvias crossnationaldifferencesinclinicallysignificantcannabisproblemsepidemiologicevidencefromcannabisonlysmokersintheunitedstatesmexicoandcolombia AT medinamoramariae crossnationaldifferencesinclinicallysignificantcannabisproblemsepidemiologicevidencefromcannabisonlysmokersintheunitedstatesmexicoandcolombia AT posadavillajose crossnationaldifferencesinclinicallysignificantcannabisproblemsepidemiologicevidencefromcannabisonlysmokersintheunitedstatesmexicoandcolombia AT anthonyjamesc crossnationaldifferencesinclinicallysignificantcannabisproblemsepidemiologicevidencefromcannabisonlysmokersintheunitedstatesmexicoandcolombia |